Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Topical Capsaicin for Neuropathic Pain in Pediatric Sickle Cell Disease
NCT03899246Phase 1Completed
- Sponsor
- Children's Hospital of Michigan
- Start
- Jul 2019
- Primary completion
- Mar 2020
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capsaicin 8% patch in neuropathic pain, sponsored by Children's Hospital of Michigan. Primary endpoints: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE Criteria at 9 months, Compliance with Serum Substance P Levels at 9 months and 2 more. Started Jul 2019; status: completed.
02
Drugs
capsaicin 8% patch
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT03899246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03899246.